Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.

Stephan DobnerBenedikt BernhardLorenz NinckMonika WieserAdam BakulaAndreas WahlValentin KöchliGiancarlo SpanoMartina Boscolo BertoElena ElchinovaYasaman SafarkhanloStefan StorteckyJonathan SchützeIsaac ShiriLukas HunzikerChristoph Gräni

Published in: ESC heart failure (2024)

Compared with untreated ATTR-CM patients, initiation of tafamidis preserved CMR-measured biventricular function and reduced LV mass at 12 months. ECV and native T1-mapping did not change significantly comparable to baseline in both groups.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
heart failure
peritoneal dialysis
prognostic factors
high resolution
left ventricular
patient reported outcomes
patient reported
cardiac resynchronization therapy